Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:GOSSNASDAQ:TYMENASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$10.91-0.6%$9.51$7.08▼$20.60$224.03M1.3873,783 shs70,909 shsGOSSGossamer Bio$1.18+11.3%$1.07$0.50▼$1.55$268.12M1.881.59 million shs2.62 million shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsYMABY-mAbs Therapeutics$4.41+7.3%$4.70$3.84▼$17.78$199.41M0.71325,743 shs163,173 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+2.04%-1.79%+24.21%-4.75%-34.59%GOSSGossamer Bio+3.92%+8.25%+6.61%+6.68%+49.82%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%YMABY-mAbs Therapeutics-3.29%-0.48%-8.67%-31.16%-75.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.5536 of 5 stars1.04.00.00.02.70.00.0GOSSGossamer Bio4.0848 of 5 stars3.52.00.04.74.01.70.0TYMETyme TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AYMABY-mAbs Therapeutics3.8228 of 5 stars4.43.00.00.02.44.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$7.00-35.84% DownsideGOSSGossamer Bio 3.00Buy$7.50535.59% UpsideTYMETyme Technologies 0.00N/AN/AN/AYMABY-mAbs Therapeutics 2.82Moderate Buy$17.40294.56% UpsideCurrent Analyst Ratings BreakdownLatest TYME, AMRN, YMAB, and GOSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.003/21/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $12.003/18/2025GOSSGossamer BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/14/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.003/5/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $18.003/5/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.003/5/2025YMABY-mAbs TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$11.00 ➝ $7.003/3/2025YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$23.00(Data available from 5/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M0.98N/AN/A$1.35 per share8.08GOSSGossamer Bio$114.70M2.34N/AN/A$0.28 per share4.21TYMETyme TechnologiesN/AN/AN/AN/A$0.47 per shareN/AYMABY-mAbs Therapeutics$87.69M2.27N/AN/A$2.32 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$4.00N/AN/AN/A-16.33%-7.22%-4.96%5/7/2025 (Estimated)GOSSGossamer Bio-$179.82M-$0.26N/AN/AN/AN/A-127.28%-22.12%5/6/2025 (Estimated)TYMETyme Technologies-$23.63M-$0.14N/A∞N/AN/A-28.30%-26.21%N/AYMABY-mAbs Therapeutics-$21.43M-$0.67N/AN/AN/A-28.22%-24.61%-18.49%5/6/2025 (Estimated)Latest TYME, AMRN, YMAB, and GOSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025AMRNAmarin-$0.06N/AN/AN/A$50.75 millionN/A5/6/2025Q1 2025GOSSGossamer Bio-$0.19N/AN/AN/A$3.95 millionN/A5/6/2025Q1 2025YMABY-mAbs Therapeutics-$0.21N/AN/AN/A$19.97 millionN/A3/18/2025Q4 2024GOSSGossamer Bio-$0.15-$0.15N/A-$0.15$7.02 million$9.38 million3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 million3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/ATYMETyme TechnologiesN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11GOSSGossamer Bio3.646.746.74TYMETyme TechnologiesN/A14.0614.06YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%GOSSGossamer Bio81.23%TYMETyme Technologies16.69%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%GOSSGossamer Bio5.00%TYMETyme Technologies16.90%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.53 million402.62 millionOptionableGOSSGossamer Bio180227.22 million215.27 millionOptionableTYMETyme Technologies17172.21 million143.10 millionOptionableYMABY-mAbs Therapeutics15045.22 million34.71 millionOptionableTYME, AMRN, YMAB, and GOSS HeadlinesRecent News About These CompaniesY-mAbs Therapeutics (YMAB) Projected to Post Earnings on TuesdayMay 1 at 9:32 AM | marketbeat.comJPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 30 at 3:04 AM | marketbeat.comEarnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to DeclineApril 29 at 11:05 AM | zacks.comBoothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 29 at 6:24 AM | marketbeat.comY-mAbs Therapeutics announces presentation of PK data of CD38-SADAApril 28, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measuresApril 27, 2025 | finance.yahoo.comY-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual MeetingApril 27, 2025 | globenewswire.comBrookline Capital Management Weighs in on YMAB Q1 EarningsApril 27, 2025 | marketbeat.comY-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platformApril 26, 2025 | markets.businessinsider.comYMAB Q1 EPS Estimate Reduced by Brookline Capital ManagementApril 26, 2025 | americanbankingnews.comY-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of AmericaApril 24, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Underperform" at Bank of AmericaApril 24, 2025 | americanbankingnews.comY-mAbs Therapeutics downgraded to Underperform from Neutral at BofAApril 23, 2025 | markets.businessinsider.comY-mAbs downgraded to Underperform at BofA on tough near-term setupApril 23, 2025 | markets.businessinsider.comY-mAbs drops as Bank of America downgrades on headwinds to DanyelzaApril 23, 2025 | msn.comWhy Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 7.47%April 23, 2025 | aaii.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.April 16, 2025 | cnn.comY-mAbs Therapeutics: A Yawn From The Market Means OpportunityApril 11, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTYME, AMRN, YMAB, and GOSS Company DescriptionsAmarin NASDAQ:AMRN$10.91 -0.07 (-0.64%) Closing price 04:00 PM EasternExtended Trading$10.90 -0.01 (-0.09%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Gossamer Bio NASDAQ:GOSS$1.18 +0.12 (+11.32%) Closing price 04:00 PM EasternExtended Trading$1.18 0.00 (0.00%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Tyme Technologies NASDAQ:TYMETyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Y-mAbs Therapeutics NASDAQ:YMAB$4.41 +0.30 (+7.30%) Closing price 04:00 PM EasternExtended Trading$4.41 0.00 (0.00%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Microsoft Crushes Earnings, What’s Next for MSFT Stock? 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
